Drug intelligence / Profile preview

FYB210

Development stage: Preclinical
Lead developer: Formycon

Overview

FYB210 is an undisclosed biosimilar candidate developed by Formycon. As of early 2025, the specific reference product and detailed mechanism of action for FYB210 have not been publicly disclosed. It is part of Formycon’s advanced biosimilar development pipeline, which targets blockbuster biopharmaceuticals in major therapeutic areas such as immunology, ophthalmology, and immuno-oncology. The drug is currently in preclinical development and represents a potential future competitor to existing high-revenue biologic therapies[1][2][4].

Beyond the preview

Go deeper on FYB210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FYB210.

Explore the full profile